口服凝血剂的进展
Advances in Oral Coagulants.
作者信息
Pollak Eleanor S
机构信息
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, and Children's Hospital of Philadelphia and the Philadelphia VA Medical Center.
出版信息
EJIFCC. 2013 Jan 16;23(4):150-3. eCollection 2013 Jan.
Abstract
This article reviews current and future treatment practices concerning oral anticoagulants. In the second decade of the 21st millennium clinicians can finally treat thrombotic disease with long-awaited new oral anticoagulant medications. In addition, improvements have been made in managing warfarin, the traditional but far from obsolete medication. The first part of this review will cover current advances with warfarin treatment. The second portion will discuss specific active coagulation factor inhibitors, the new oral anticoagulants.
摘要
本文综述了目前及未来有关口服抗凝剂的治疗方法。在21世纪的第二个十年里，临床医生终于可以使用期待已久的新型口服抗凝药物来治疗血栓性疾病了。此外，在管理传统但远未过时的药物华法林方面也取得了进展。本综述的第一部分将涵盖华法林治疗的当前进展。第二部分将讨论特定的活性凝血因子抑制剂，即新型口服抗凝剂。
相似文献
1
Advances in Oral Coagulants.
EJIFCC. 2013 Jan 16;23(4):150-3. eCollection 2013 Jan.
2
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
BMJ. 2017 Feb 10;356:j510. doi: 10.1136/bmj.j510.
3
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3.
4
[Pharmacogenomic Research in Direct Oral Anticoagulants].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020 Aug 30;42(4):562-565. doi: 10.3881/j.issn.1000-503X.11423.
5
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
J Am Heart Assoc. 2018 Apr 13;7(8):e008643. doi: 10.1161/JAHA.118.008643.
6
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Ann Pharmacother. 2015 Mar;49(3):278-84. doi: 10.1177/1060028014563950. Epub 2014 Dec 16.
7
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
8
Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.
J Am Heart Assoc. 2017 Feb 14;6(2):e004517. doi: 10.1161/JAHA.116.004517.
9
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725.
10
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36. doi: 10.1093/ehjcvp/pvw031. Epub 2016 Sep 27.
本文引用的文献
1
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation.
Expert Rev Cardiovasc Ther. 2012 Dec;10(12):1471-80. doi: 10.1586/erc.12.148.
2
What did we learn from new oral anticoagulant treatment?
Thromb Res. 2012 Oct;130 Suppl 1(Suppl 1):S41-3. doi: 10.1016/j.thromres.2012.08.271.
3
Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.
J Thromb Thrombolysis. 2012 Nov;34(4):437-45. doi: 10.1007/s11239-012-0781-z.
4
New oral anticoagulants in the ED setting: a review.
Am J Emerg Med. 2012 Nov;30(9):2046-54. doi: 10.1016/j.ajem.2012.04.005. Epub 2012 Jul 12.
5
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28.
6
More light at the end of the tunnel - apixaban in atrial fibrillation.
Expert Opin Investig Drugs. 2012 Aug;21(8):1235-9. doi: 10.1517/13543784.2012.696611. Epub 2012 Jun 13.
7
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
8
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
Am J Hematol. 2012 May;87 Suppl 1:S141-5. doi: 10.1002/ajh.23202. Epub 2012 Apr 4.
9
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.
Nat Rev Cardiol. 2012 Feb 28;9(7):385-91. doi: 10.1038/nrcardio.2012.19.
10
Apixaban for the prevention of stroke in atrial fibrillation.
Expert Rev Cardiovasc Ther. 2012 Feb;10(2):143-9. doi: 10.1586/erc.11.187.
Zotero 插件